Ipca signs agreement with CDRI

New Delhi, Aug 27: Mumbai-based Ipca Laboratories Ltd today said it has entered into a collaborative-cum-license agreement with Central Drug Research Institute (CDRI).

As per the agreement, the company will further develope its compound 99/411, a promising synthetic substitute for drugs based on Artemisinin derived from the plant Artemisia annua.

CDRI, Lucknow is a premier Research Institute of CSIR, actively engaged in research areas of national priorities like anti-malarial, tuberculosis and reproductive health along with life style and age related disorders.

Artemisinin based combination therapy has been recommended by WHO for the treatment of P falciparum malaria.

A synthetic substitute of artemisinin will be a major break through in cost effective management of falciparum malaria and multi drug resistant falciparum malaria in clinical practice.

UNI